313 related articles for article (PubMed ID: 20947507)
1. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
[TBL] [Abstract][Full Text] [Related]
2. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
3. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
6. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.
Chin M; Herscovitch M; Zhang N; Waxman DJ; Gilmore TD
Oncogene; 2009 May; 28(20):2100-11. PubMed ID: 19377508
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
9. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
[TBL] [Abstract][Full Text] [Related]
10. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].
Škunca Z; Planinc-Peraica A
Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782
[TBL] [Abstract][Full Text] [Related]
11. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
Torlakovic E; Malecka A; Myklebust JH; Tierens A; Aasheim HC; Nesland JM; Smeland E; Kvaløy S; Delabie J
J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
[TBL] [Abstract][Full Text] [Related]
12. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
13. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
14. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
15. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
17. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
18. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
